印度采用一次性注射器喷射注射器接种麻疹-腮腺炎-风疹疫苗的免疫原性与安全性:一项随机、平行组、非劣效性试验
在印度15-18月龄已接种麻疹疫苗的幼儿中开展随机非劣效性试验,比较一次性注射器喷射注射器(DSJI)与针筒注射器(N-S)皮下接种MMR疫苗。每组170人,接种后35天麻疹、腮腺炎、风疹血清IgG抗体阳性率组间差异均无统计学意义,GMT差异亦无统计学意义。DSJI组局部反应报告数多于N-S组,多为轻度,全身不良事件两组相似。
要点
- DSJI接种MMR疫苗的免疫原性与N-S接种相当,各抗体阳性率及GMT组间差异均无统计学意义。
- DSJI组报告173例征集性局部反应,N-S组112例,多为轻度,耐受性良好。
- 156例征集性全身不良事件多为轻度,两组发生率相似。
核心结论
- 经DSJI接种MMR疫苗的免疫原性与N-S接种相当,安全性特征相似,唯注射部位反应DSJI组更多且耐受良好。
研究设计与样本
- 在印度开展的随机、平行组、非劣效性临床试验,对象为15-18月龄且9月龄时已接种麻疹疫苗的幼儿。
- MMR疫苗经DSJI或针筒注射器(N-S)皮下接种,每组170人。
- 接种后35天检测麻疹、腮腺炎、风疹血清IgG抗体,并收集接种后14天内的征集性反应。
主要发现
- 接种后35天,DSJI组与N-S组麻疹血清阳性率分别为97.5%[95%CI(93.8%,99.3%)]与98.7%[95%CI(95.5%,99.8%)],差异无统计学意义。
- 腮腺炎血清阳性率DSJI组98.8%[95%CI(95.6%,99.8%)] vs N-S组98.7%[95%CI(95.5%,99.8%)],差异无统计学意义。
- 风疹血清阳性率DSJI组98.8%[95%CI(95.6%,99.8%)] vs N-S组100%[95%CI(97.7%,100.0%)],差异无统计学意义。
- DSJI组报告173例征集性局部反应,N-S组报告112例,多为轻度;156例征集性全身不良事件多为轻度,两组发生率相似。
关键数值与推荐
- 非劣效性判定标准为组间血清阳性率差异的95%CI上限小于10%。
- 接种后35天评估麻疹、腮腺炎、风疹血清IgG抗体阳性率与GMT。
- 征集性反应通过结构化日记收集,时间为接种后14天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We conducted a randomized, non-inferiority, clinical study of MMR vaccine by a disposable-syringe jet injector (DSJI) in toddlers in India in comparison with the conventional administration. METHODS: MMR vaccine was administered subcutaneously by DSJI or needle-syringe (N-S) to toddlers (15-18 months) who had received a measles vaccine at 9 months. Seropositivity to measles, mumps, and rubella serum IgG antibodies was assessed 35 days after vaccination. Non-inferiority was concluded if the upper limit of the 95% CI for the difference in the percent of seropositive between groups was less than 10%. Solicited reactions were collected for 14 days after vaccination by using structured diaries. RESULTS: In each study group, 170 subjects received MMR vaccine. On day 35, seropositivity for measles was 97.5% [95% CI (93.8%, 99.3%)] in the DSJI group and 98.7% [95% CI (95.5%, 99.8%)] in the N-S group; for mumps, 98.8% [95% CI (95.6%, 99.8%)] and 98.7% [95% CI (95.5%, 99.8%)]; and for rubella, 98.8% [95% CI (95.6%, 99.8%)] and 100% [95% CI (97.7%, 100.0%)]; none of the differences were significant. The day 35 post-vaccination GMTs in DSJI and N-S groups were measles: 5.48 IU/ml [95% CI (3.71, 8.11)] and 5.94 IU/ml [95% CI (3.92, 9.01)], mumps: 3.83 ISR [95% CI (3.53, 4.14)] and 3.66 ISR [95% CI (3.39, 3.95)] and rubella: 95.27 IU/ml [95% CI (70.39, 128.95)] and 107.06 IU/ml [95% CI (79.02, 145.06)]; none of the differences were significant. The DSJI group reported 173 solicited local reactions and the N-S group reported 112; most were mild grade. Of the total of 156 solicited systemic adverse events, most were mild, and incidence between the two groups was similar. CONCLUSIONS: MMR vaccination via DSJI is as immunogenic as vaccination by N-S. Safety profile of DSJI method is similar to N-S except for injection site reactions which are more with DSJI and are well-tolerated. Registration US National Institutes of Health clinical trials identifier - NCT02253407. Clinical trial registry of India identifier - CTRI/2013/05/003702.
引用
- Bavdekar A, Oswal J, Ramanan PV, et al. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. Vaccine. 2018. PMID: 29395526. doi:10.1016/j.vaccine.2018.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。